Health Research Methodology Graduate Program, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada.
BMJ Open. 2021 Nov 1;11(11):e054777. doi: 10.1136/bmjopen-2021-054777.
Major depressive disorder (MDD or depression) is prevalent among adults aged 65 years and older. The effectiveness and safety of interventions used to treat depression is often assessed through randomised controlled trials (RCTs). However, heterogeneity in the selection, measurement and reporting of outcomes in RCTs renders comparisons between trial results, interpretability and generalisability of findings challenging. There is presently no core outcome set (COS) for use in RCTs that assess interventions for older adults with MDD. We will conduct a methodological review of the literature for outcomes reported in trials for adults 65 years and older with depression to assess the heterogeneity of outcome measures.
RCTs evaluating pharmacotherapy, psychotherapy, or any other treatment intervention for older adults with MDD published in the last 10 years will be located using electronic database searches (MEDLINE, Embase, PsycINFO and the Cochrane Central Register of Controlled Trials). Reviewers will conduct title and abstract screening, full-text screening and data extraction of trials eligible for inclusion independently and in duplicate. Outcomes will be synthesised and mapped to core outcome-domain frameworks. We will summarise characteristics associated with trials and outcomes.
We hope that findings from our methodological review will reduce variability in outcome selection, measurement and reporting and facilitate the development of a COS for older adults with MDD. Our review will also inform evidence synthesis efforts in identifying the best treatment practices for this clinical population. Ethics approval is not required, as this study is a literature review.
CRD42021244753.
重度抑郁症(MDD 或抑郁症)在 65 岁及以上的成年人中较为普遍。用于治疗抑郁症的干预措施的有效性和安全性通常通过随机对照试验(RCT)来评估。然而,RCT 中结局的选择、测量和报告的异质性使得对试验结果的比较、发现的可解释性和普遍性具有挑战性。目前尚无用于评估老年人 MDD 干预措施的 RCT 核心结局集(COS)。我们将对过去 10 年中评估老年人 MDD 的药物治疗、心理治疗或任何其他治疗干预的 RCT 报告的结局进行文献方法学回顾,以评估结局测量的异质性。
将使用电子数据库搜索(MEDLINE、Embase、PsycINFO 和 Cochrane 对照试验中心注册)来定位评估老年人 MDD 的药物治疗、心理治疗或任何其他治疗干预的 RCT。审查员将独立地、重复地进行标题和摘要筛选、合格试验的全文筛选和数据提取。结局将被综合并映射到核心结局领域框架。我们将总结与试验和结局相关的特征。
我们希望我们的方法学综述的结果将减少结局选择、测量和报告的变异性,并促进为 MDD 老年人制定 COS。我们的综述还将为识别针对这一临床人群的最佳治疗实践的证据综合工作提供信息。由于这是一项文献综述,因此不需要伦理批准。
PROSPERO 注册号:CRD42021244753。